Cabaletta Bio (NASDAQ: CABA) posts updated corporate deck for investors

Rhea-AI Filing Summary

Cabaletta Bio, Inc. furnished an updated corporate presentation for investors under a Regulation FD disclosure. On September 3, 2025, the company posted this new “Corporate Presentation” to the “Investors & Media” section of its website and furnished it as Exhibit 99.1. The presentation is dated September 2025 and is provided as supplemental information only, as it is being furnished rather than filed and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

false000175913800017591382025-09-032025-09-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 03, 2025

CABALETTA BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39103	82-1685768
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2929 Arch Street Suite 600
Philadelphia, Pennsylvania				19104
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (267) 759-3100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		CABA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 3, 2025, Cabaletta Bio, Inc. ("Cabaletta" or the “Company”) posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Cabaletta Bio, Inc. Corporate Presentation, dated September 2025, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CABALETTA BIO, INC.
Date: September 3, 2025		By:	/s/ Steven Nichtberger
			Steven Nichtberger
			Chief Executive Officer and President (Principal Executive Officer)

FAQ

What did Cabaletta Bio (CABA) disclose in this 8-K filing?

Cabaletta Bio disclosed that it posted an updated corporate presentation on its website and furnished the same presentation as Exhibit 99.1 under a Regulation FD disclosure item.

Where can investors find Cabaletta Bio’s updated corporate presentation?

The updated corporate presentation is available in the “Investors & Media” section of Cabaletta Bio’s website at www.cabalettabio.com and is also furnished as Exhibit 99.1.

How is the Cabaletta Bio corporate presentation treated under SEC rules?

The information in the corporate presentation, furnished under Item 7.01, is considered “furnished” rather than “filed” and is not subject to Section 18 liabilities of the Exchange Act or incorporated by reference into other filings unless specifically stated.

What is Exhibit 99.1 in Cabaletta Bio’s 8-K?

Exhibit 99.1 is Cabaletta Bio, Inc.’s updated corporate presentation dated September 2025, which was furnished with this report for investor information.

Who signed this Cabaletta Bio 8-K report?

The report was signed on behalf of Cabaletta Bio, Inc. by Steven Nichtberger, the company’s Chief Executive Officer and President and its principal executive officer.

Is the updated Cabaletta Bio investor presentation incorporated into other SEC filings?

The presentation is not incorporated into other Securities Act or Exchange Act filings unless a future filing expressly incorporates it by specific reference.